Corticotropin Releasing Factor-Induced CREB Activation in Striatal Neurons Occurs via a Novel Gβγ Signaling Pathway by Stern, Christopher M. et al.
Corticotropin Releasing Factor-Induced CREB Activation
in Striatal Neurons Occurs via a Novel Gbc Signaling
Pathway
Christopher M. Stern
1,2, Jessie I. Luoma
1,2, John Meitzen
2, Paul G. Mermelstein
1,2*
1Graduate Program in Neuroscience, University of Minnesota, Minneapolis, Minnesota, United States of America, 2Department of Neuroscience, University of Minnesota,
Minneapolis, Minnesota, United States of America
Abstract
The peptide corticotropin-releasing factor (CRF) was initially identified as a critical component of the stress response. CRF
exerts its cellular effects by binding to one of two cognate G-protein coupled receptors (GPCRs), CRF receptor 1 (CRFR1) or 2
(CRFR2). While these GPCRs were originally characterized as being coupled to Gas, leading to downstream activation of
adenylyl cyclase (AC) and subsequent increases in cAMP, it has since become clear that CRFRs couple to and activate
numerous other downstream signaling cascades. In addition, CRF signaling influences the activity of many diverse brain
regions, affecting a variety of behaviors. One of these regions is the striatum, including the nucleus accumbens (NAc). CRF
exerts profound effects on striatal-dependent behaviors such as drug addiction, pair-bonding, and natural reward. Recent
data indicate that at least some of these behaviors regulated by CRF are mediated through CRF activation of the
transcription factor CREB. Thus, we aimed to elucidate the signaling pathway by which CRF activates CREB in striatal
neurons. Here we describe a novel neuronal signaling pathway whereby CRF leads to a rapid Gbc- and MEK-dependent
increase in CREB phosphorylation. These data are the first descriptions of CRF leading to activation of a Gbc-dependent
signaling pathway in neurons, as well as the first description of Gbc activation leading to downstream CREB
phosphorylation in any cellular system. Additionally, these data provide additional insight into the mechanisms by which
CRF can regulate neuronal function.
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Introduction
Stress is any actual or perceived disturbance of an organism’s
environment. An acute stress response, which includes the release
of corticotropin-releasing factor (CRF), is often necessary for the
preservation of organismal integrity during brief anxiety situations.
CRF binding to its cognate G-protein coupled receptors (GPCRs),
CRF receptor 1 (CRFR1) and 2 (CRFR2), mediates the influence
of CRF on brain cells. However, in addition to their beneficial role
in an acute stress response, both stress and CRF have been
implicated in pathological disease states, including drug addiction.
Several lines of evidence suggest that stress, and CRF in
particular, influence addiction and addictive behaviors. Drugs of
abuse have been shown to activate the hypothalamic-pituitary-
adrenal (HPA) axis [1], initiating the stress response. Human
individuals with a history of chronic stress are more likely to
become addicts, and previously abstinent addicts are more likely to
relapse following exposure to an acute stressor [1–3]. A stress event
both increases drug-seeking behavior as well as facilitates
conditioned-place preference to drugs of abuse in animal models
of addiction [4–10]. Furthermore, stress and CRF potentiate the
rewarding effects of drugs of abuse [11].
Recent findings suggest that CRF-induced CREB phosphory-
lation within the nucleus accumbens (NAc) underlies at least some
of these effects of stress on addictive behaviors [11]. As CREB
signaling in NAc is critical for the rewarding actions of drugs of
abuse [12–16], CRF activation of CREB represents a putative
molecular mechanism by which stress could manipulate the neural
circuitry underlying drug addiction.
Not surprisingly, the effects of CRF on NAc functioning are not
limited to actions related to drug abuse, but also affect the
rewarding actions of more physiological stimuli. For example,
CRF acting in NAc plays an essential role in prairie-vole pair
bonding [17], as well as enhances the incentive salience of a
sucrose reward [18]. And while research thus far has focused on
the NAc, CRF neurotransmission is also an essential component to
connectivity in the dorsal striatum [19–22].
Although the influence of CRF on striatal functioning has been
established, the molecular mechanisms by which this occurs
remain unclear. Given the known relevance for CRF activation of
CREB, we characterized the intracellular signaling pathway by
which this occurs. While CRFRs are classically thought of as Gas-
coupled GPCRs that exert their effects via activation of adenylyl
cyclase (AC) and subsequent increases in the second messenger
cAMP [23,24], these receptors have since been shown to couple to
multiple G-protein signaling cascades in neurons [25]. Through
use of pharmacological and genetic approaches, we report a novel
signaling pathway whereby CRF leads to a rapid Gbc-dependent
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signaling. In addition to illuminating the pathways by which CRF
affects striatal neurons, this is the first example of CRF leading to
downstream Gbc-dependent signaling, as well as the first example
of Gbc activation leading to CREB phosphorylation.
Results
CRF Induces Rapid CREB Phosphorylation via Activation
of CRFR1
Stress-induced activation of CREB in the striatum requires
CRFR1 activation [11]. Thus, we attempted to determine whether
CRF can lead to CREB phosphorylation (pCREB) in cultured
striatal neurons from 1- to 2-day old rat pups, and if so, through
which molecular pathway(s). Indeed, a 15-min application of CRF
(40 nM) significantly increased CREB phosphorylation relative to
vehicle-stimulated control neurons (Figure 1), but had no effect on
total CREB staining (Figure S1). When measuring pCREB
fluorescence, CRF produced an observable shift in the population
response of striatal neurons (Figure 1C). Specifically, plotting the
pCREB data as a cumulative histogram revealed that, CRF
produced a large shift in pCREB fluorescence intensity in
approximately 80% of the striatal neurons (Figure 1C). Further-
more, CRF increased CREB phosphorylation in a concentration-
dependent manner with an EC50 = 0.3 nM (Figure 1D), consistent
with a CRFR-mediated event (binding affinity of CRF for CRFR1
, 5–10 nM [26]). CRF-induced increases in pCREB occurred in a
rapid and time-dependent manner (t,3.5 minutes), with extended
exposure (1 hr) producing apparent desensitization (Figure 1E).
The striatum is composed of two major sub-regions, the dorsal
striatum (i.e. caudate/putamen) and nucleus accumbens (NAc). To
determine whether CRF-induced CREB phosphorylation is
restricted to neurons from one of these two anatomical regions,
we created dorsal striatum ‘‘enriched’’ and NAc ‘‘enriched’’
cultures. Both cultures displayed similarly robust increases in
CREB phosphorylation upon CRF application (data not shown),
suggesting that there are no overt differences in CRF-responsive-
ness between these two brain regions. Thus, we performed our
remaining experiments in whole striatal cultures.
The striatum expresses both CRFRs, although CRFR1 to a greater
extent than CRFR2 [27–30]. We confirmed expression of both
receptors in our cultured neuronal system using real-time PCR (data
not shown). To determine whether CRF-induced CREB phosphor-
ylation occurs via activation of these classic CRFRs, we pre-incubated
our striatal neurons with the non-specific CRFR peptide antagonist
astressin (50 nM).IndicativeofaCRFR-mediatedevent,thistreatment
completely abolished CRF-induced CREB phosphorylation
(Figure 2A). Next, we sought to determine which receptor mediates
Figure 1. CRF rapidly stimulates CREB phosphorylation. (A) Immunolabeled confocal images of cultured striatal neurons from 1- to 2-day old
rat pups with MAP2 (red) and pCREB (green). Neurons stimulated with CRF (40 nM) for 15 min exhibited increased CREB phosphorylation (Scale Bar
=2 0mm). (B) Quantification of immunostaining, revealing CRF-mediated CREB phosphorylation (p,0.0001). (C) CRF induced a rightward shift in the
plot of pCREB fluorescence intensity of approximately 80% of striatal neurons (D) CRF increased CREB phosphorylation in a concentration-dependent
manner, with EC50 = 0.3 nM. Concentrations $ 4 nM induced a signal that differed with statistical significance from vehicle-stimulated (NS) neurons.
(E) Time course of 40 nM CRF-induced CREB phosphorylation, with t = 3.5 min. Statistically different groups are denoted by different alphabetical
characters in corresponding bar graphs in this and subsequent figures. P-values ,0.05 were considered a priori as significant.
doi:10.1371/journal.pone.0018114.g001
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CRFR1 antagonist CP154526 (100 nM) eliminated CRF-induced
CREB phosphorylation (Figure 2B). In addition, a 15 min application
of the CRFR1-specific agonist stressin-1 (STR; 70 nM) mimicked the
effect of CRF, and this effect was also blocked with CP154526
(Figure 2C). To determine any putative role of CRFR2 in CRF-
induced CREB phosphorylation, we utilized two CRFR2-preferring
peptide antagonists. Both antisauvagine-30 (100 nM; Figure 2D) and
K41498 (10 nM) (not shown) failed to block CRF-induced CREB
phosphorylation. Together, these data strongly demonstrate that CRF
induced CREB phosphorylation in striatal neurons is mediated
exclusively through CRFR1, with CRFR2 playing no discernable role.
CRF Does Not Induce CREB Phosphorylation via the AC/
cAMP/PKA Pathway
CRFR1 is primarily thought of as a GPCR that signals through
Gas to produce subsequent increases in cAMP. Hence, we decided
first to test the hypothesis that CRF activation of CRFR1 leads to
an AC/cAMP/PKA-dependent increase in CREB phosphoryla-
tion. To assay for the involvement of this pathway, we began with
inhibition of PKA. A PKA-specific concentration [31,32] of the
protein kinase inhibitor H-89 (2 mM) failed to block CRF-induced
CREB phosphorylation (Figure 3A). Importantly, this concentra-
tion of H89 attenuated CREB phosphorylation stimulated by the
AC agonist forskolin (FSK; 25 mM), which signals to CREB
through multiple cAMP-responsive proteins including PKA
(Figure 3A). Given this unexpected result, we attempted to block
CRF-induced CREB phosphorylation with three additional PKA
antagonists: the cell permeable peptide PKA inhibitor PKI, 14–22
amide (1 mM), KT5720 (1 mM), and cAMPS-Rp, triethylammo-
nium salt (10 mM). All three compounds also failed to eliminate
CRF-induced CREB phosphorylation (data not shown). Together,
these data demonstrate that PKA is not involved in CRF-induced
CREB phosphorylation in striatal neurons.
We next determined whether CRF was in fact eliciting increases
in cAMP under conditions in which CRF was producing CREB
phosphorylation. Hence, we quantified cAMP concentrations
following the CRF stimulation paradigm used to elicit increases
in CREB phosphorylation. To prevent potential loss of the cAMP
signal during the agonist stimulations, the phosphodiesterase
inhibitor IBMX (75 mM) was included both prior to and during
stimulation. Exposure of striatal cultures to CRF (40 nM) for
Figure 2. CRFR1 mediates CRF-induced CREB phosphorylation. (A) CRF-mediated CREB phosphorylation was blocked by the non-specific
CRFR antagonist astressin (50 nM; F=20.19), (B) and the CRFR1-specfic antagonist CP154526 (100 nM; F=17.40). (C) CRF-induced CREB
phosphorylation was mimicked by the CRFR1 agonist stressin-1 (STR; 70 nM). STR-induced CREB phosphorylation was also blocked by CP154526
(F=15.99). (D) The CRFR2-specific antagonist antisauvagine-30 (100 nM) had no effect on CRF-induced CREB phosphorylation (F=17.10).
doi:10.1371/journal.pone.0018114.g002
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measurable increase in cAMP concentration (Figure 3B). In fact,
stimulation of striatal cultures for 15 min with various concentra-
tions of CRF up to and including 400 nM (Figure 3C) failed to
induce a significant accumulation of cAMP. As a positive control
for our assay [33], a 15 min application of the b-adrenergic
receptor agonist isoproterenol (ISO; 10 mM) resulted in a
significant increase in cAMP (Figure 3B).
To directly test whether cAMP signaling played a role in CRF-
induced CREB phosphorylation, we treated striatal cultures with
the AC antagonist SQ22536 (90 mM). While SQ22536 completely
blocked ISO-induced cAMP formation (Figure 3D), it failed to
affect CRF-induced CREB phosphorylation (Figure 3E). Togeth-
er, these data demonstrate that rapid CRF-induced CREB
phosphorylation in striatal neurons operates independently of
AC, cAMP, and PKA signaling.
CRF Induces CREB Phosphorylation via Calcium-
Independent MAPK Signaling
Independent of PKA, several downstream kinase pathways have
been shown to regulate CREB phosphorylation [34,35]. One such
kinase is CaMKIV. However, blocking CaMK activation with
KN-93 (2 mM) had no effect on CRF-induced CREB phosphor-
ylation (Figure 4A), although this concentration of KN-93 blocks
depolarization-induced CREB phosphorylation [36].
MAPK signaling is another pathway that has been shown
capable of CREB activation in a variety of neuronal preparations.
In contrast to previous experiments, the MEK (MAPK kinase)
inhibitor U0126 (10 mM) blocked CRF-induced CREB phosphor-
ylation (Figure 4B). A second MEK antagonist, PD98059 (25 mM),
yielded a similar result (data not shown). MAPK-dependent CREB
phosphorylation is often calcium dependent, following calcium
entry through L-type calcium channels, or release of calcium from
intracellular stores. However, CRF-mediated CREB phosphory-
lation was not affected by either the L-type calcium channel
blocker nifedipine (5 mM; Figure 4C) or by chelating intracellular
calcium through pre-incubation with BAPTA-AM (Figure 4D).
Removing extracellular calcium during CRF stimulation also had
no effect on CRF-mediated CREB phosphorylation (data not
shown). Thus, CRF activation of MAPK signaling appears to be
calcium independent.
CRF Induces CREB Phosphorylation via a Gbc-Dependent
Mechanism
We next decided to test the involvement of several upstream
signalers that could lead to downstream MAPK activation,
Figure 3. CRF-induced CREB phosphorylation occurs independently of the AC/cAMP/PKA pathway. (A) A PKA-specific concentration of
the protein kinase inhibitor H89 (2 mM) failed to block CRF-induced CREB phosphorylation, but attenuated forskolin (FSK)-induced CREB
phosphorylation (F=35.78). (B) In the presence of the phosphodiesterase inhibitor IBMX (75 mM), CRF (40 nM) failed to increase cAMP during the
time-course in which it increases pCREB. The b-adrenergic receptor agonist isoproterenol (ISO; 10 mM) was used as a positive control (F=3226). (C)
Several concentrations of CRF up to and including 400 nM failed to increase cAMP accumulation (in the presence of IBMX). (D) Inhibiting AC activity
with SQ22536 (90 mM) completely blocked ISO-induced cAMP accumulation (F=101.4). (E) Inhibition of AC with SQ22536 had no effect on CRF-
induced CREB phosphorylation (F=17.10).
doi:10.1371/journal.pone.0018114.g003
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ROCK, and PI3K. We utilized pharmacological blockers for
each of these molecules to test for any contribution in CRF-
induced CREB phosphorylation. Remarkably, inhibitors of Akt
(10-DEBC; 5 mM), RTKs (K252A; 100 nM), Ras (XRP44X;
2 mM), Raf (GW5074; 1 mM) ROCK (H-1152; 500 nM), and
PI3K (wortmannin; 500 nM) all failed to affect CRF-induced
CREB phosphorylation (data not shown). Unable to identify an
intermediary signaling molecule upstream of MEK but down-
stream of CRFR1, we decided to test for the involvement of
different G-protein subunits in CRF-induced CREB phosphory-
lation.
To test for a Gbc-dependent mechanism in CRF-induced
CREB phosphorylation, we utilized the Gbc-specific inhibitor
gallein (75 mM) [37]. In support of a role for Gbc, CRF failed to
induce CREB phosphorylation in the presence of this drug
(Figure 5A). To ensure that the effect of gallein was specific to
CRF and not dampening all G-protein signaling, we stimulated
our neurons with ISO (10 mM) in the presence of gallein. Since
ISO leads to CREB phosphorylation via a Gas pathway in striatal
neurons [33], gallein should not affect ISO-dependent CREB
phosphorylation. Indeed, this was in fact the case (Figure 5B). To
verify our initial results, we blocked CRF-induced CREB
phosphorylation with a second Gbc-specific inhibitor, M119
(5 mM; Figure 5C). Again M119 had no effect on ISO-induced
CREB phosphorylation (data not shown; also see [33]).
To complement these pharmacological data, we utilized a
genetic approach to further characterize the involvement of Gbc
in CRF-induced CREB phosphorylation. Neurons were transfect-
ed with either a construct expressing mCherry or co-transfected
with the mCherry construct plus a construct expressing the peptide
motif of G-protein regulated kinase that scavenges Gbc (Grk2i),
which has previously been shown to specifically block downstream
Gbc signaling [38]. Neurons that were transfected with mCherry
alone demonstrated robust CRF-induced CREB phosphorylation.
However, neurons that were transfected with Grk2i failed to show
CRF-induced CREB phosphorylation (Figure 5D). Together,
these pharmacological and genetic data support the hypothesis
that CRF-induced CREB phosphorylation is mediated via a Gbc-
dependent signaling mechanism.
Figure 4. CRF-induced CREB phosphorylation occurs via a MEK/MAPK-dependent mechanism. (A) The CaMK inhibitor KN-93 (2 mM) did
not affect CRF-induced CREB phosphorylation (F=17.65). (B) CRF-induced CREB phosphorylation was blocked by the MEK antagonist U0126 (10 mM;
F=11.97). (C) The L-type Ca
2+ channel blocker nifedipine (5 mM) had no effect on CRF-induced CREB phosphorylation (F=18.50). (D) Chelating
intracellular calcium with BAPTA-AM (30 min incubation with 5 mM) failed to block CRF-induced CREB phosphorylation (F=12.72).
doi:10.1371/journal.pone.0018114.g004
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To identify the Ga subunit to which CRFR1 and Gbc couple in
this paradigm, we utilized toxins that specifically target functional
classes of Ga. Since functional Gbc subunits in neurons are
classically thought to associate with Gai/o, we first utilized pertussis
toxin (PTX) to specifically inhibit these Ga subunits. PTX prevents
the exchange of GDP (inactive state) for GTP (active state), thus
hindering the G-protein trimer (Gabc) from dissociating from the
GPCR, and initiating downstream signaling. Overnight (18 hr)
pretreatment of striatal neurons with PTX (0.5 mng/mL) did not
alter CRF-mediated CREB phosphorylation (Figure 6A).
Next, we targeted the Gas family, which includes Gas and Gaolf
in the striatum [39] (hereafter termed Gas), with cholera toxin
(CTX). CTX blocks inactivation of Gas by preventing the
hydrolysis of GTP (active state) to GDP (inactive state). A short
term (2 hr) pre-treatment with CTX induced a transient increase
in pCREB on its own (NS: 397.7693.5; CTX: 2809.76104.5),
confirming that Gas can signal to CREB in this paradigm.
However, to test the effect of disrupting Gas signaling on CRF-
induced CREB phosphorylation, we used long-term CTX
treatment, which allows the pCREB signal to reset, as well as
prevents Gas from re-associating with either the Gbc subunits or
the GPCR, precluding agonist-induced reactivation of this
signaling pathway. Indeed, overnight pretreatment with CTX
resulted in a complete block of CRF-induced CREB phosphor-
ylation (Figure 6B). Importantly, MAPK-mediated CREB phos-
phorylation following a 60 mM K
+ depolarization [36] was
unaffected by this treatment (Figure 6B), indicating signaling
downstream of CRFR1 was still intact.
Since AC is the primary downstream effector of Gas, and since
CRFR1 couples to Gas in striatal neurons (Figure 6), we wondered
why we failed to observe CRF-induced cAMP accumulation
(Figure 3). We hypothesized that CRFR1 is in fact organized into
discrete membrane lipid microdomains [40], which (1) facilitate
Gbc activation of downstream MAPK signaling and (2) prevents
Gas from accessing/stimulating AC. Therefore, we hypothesized
that disrupting lipid microdomains would allow Gas to activate
AC following CRF stimulation. To test this hypothesis we pre-
incubated our striatal neurons with the cholesterol chelator
methyl-b-cyclodextrin (MbCD; 10 mM), commonly used to
Figure 5. CRF-induced CREB phosphorylation occurs via a Gbc-dependent mechanism. (A) The Gbc-specific blocker gallein (75 mM)
eliminated CRF-induced CREB phosphorylation (F=6.13). (B) In contrast, gallein had no effect on CREB phosphorylation induced by the b-adrenergic
receptor agonist, isoproterenol (F=16.83). (C) An additional Gbc blocker (M119; 5 mM) also eliminated CRF-induced CREB phosphorylation (F=27.96).
(D) Neurons transfected mCherry and the Gbc inhibitory peptide Grk2i failed to exhibit CRF-induced CREB phosphorylation (F=11.26).
doi:10.1371/journal.pone.0018114.g005
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conditions, 4 mM CRF induced a significant increase in cAMP
formation in the presence of MbCD (Figure 6C), although
notably, not to the levels seen with isoproterenol (see discussion).
These data are consistent with the hypothesis that CRF is
liberating Gas subunits in order to mediate Gbc-mediated CREB
phosphorylation.
Discussion
CRF Increases CREB Phosphorylation via a Novel
Signaling Pathway
CRF signaling in neurons was initially characterized as being
mediated via the Gas-coupled CRFR1, and subsequent down-
stream activation of AC, cAMP and PKA. However, given the
recent evidence for the promiscuity of CRF coupling to
intracellular signaling pathways, and the profound influence of
CRF on NAc processes via CREB, our experiments were designed
to determine the specific signaling pathway by which CRF-
induced CREB phosphorylation in striatal neurons. Using a
combination of pharmacological and genetic approaches, we
report a novel neuronal signaling pathway whereby CRF binds to
aG as-coupled CRFR1, leading to a Gbc- and MAPK-dependent
increase in CREB phosphorylation. Notably, these data are
consistent with previous findings showing that stress-facilitation of
drug reward depends on CRFR1 and CREB activation in NAc
[11], as well as the finding that CRFR1 is the predominant CRF
receptor expressed within this brain region [27–30].
These data demonstrating CRF signaling through a non-
canonical pathway are consistent with numerous reports of
CRFRs coupling to diverse intracellular signaling pathways across
distinct neuronal populations. CRF has been shown to activate
CREB in cerebellar and hippocampal neurons [43], as well as
MAPKs in several brain regions [44]. Separate from CREB/
MAPK signaling, CRF also affects the activity of various other
kinases, second messengers, ion channels and neurotransmitter
receptors [45–51]. This diversity in cellular effects is not surprising
when one considers the ability of CRF to influence a variety of
natural and pathological behaviors [17,52–54]. However, this
report is unique among papers describing CRF signaling in
neurons in that it describes a novel upstream signaling activator at
the level of the G-protein subunit (Gbc).
Although this is the first report demonstrating that Gbc leads
to CREB activation, and that CRF and CRFR1 signal via Gbc
in neurons, there have been reports of CRF acting through
Gbc-dependent mechanisms in cell lines expressing recombi-
nant protein. These include findings that CRF effects on T-type
calcium channels [55] and intracellular calcium signaling [56]
depend on Gbc function, as well as a study that found that Gbc
is important for CRFR desensitization [57]. There is also a
precedent for activation of Gbc leading to downstream MAPK
activation in non-neuronal cell lines [58–60]. One group has
shown indirect evidence for Gbc mediated CREB activation in
cerebellar granule neurons [61] by demonstrating (1) that Gbc
subunits mediate GABAB receptor-induced ERK activation,
and (2) that GABAB-mediated CREB phosphorylation is
sensitive to MEK/ERK inhibition. Importantly, the authors
did not demonstrate in their pCREB assay that GABAB-induced
CREB phosphorylation is sensitive to Gbc inhibition. Hence,
our approach is unique in that it is the first report using a direct
assay of CREB phosphorylation to demonstrate that agonist-
induced increases in pCREB are sensitive to inhibition of Gbc
signaling. Given the diversity of Gbc signaling [58,60] and the
plethora of CRF effects in numerous brain regions and
peripheral tissues [25], future studies can test for a role of
Gbc signaling in CRF function throughout the brain and other
tissue.
The mechanism by which Gbc leads to MAPK signaling in
striatal neurons remains elusive [59,60]. One hypothesis is that an
intermediate signaling moiety couples Gbc to MEK (Figure 7). We
assayed for the involvement of signaling molecules that have
previously been shown to lead to downstream MAPK/CREB
activation, are known to be activated by Gbc, or both.
Pharmacological inhibitors/blockers of L-type calcium channels,
CaMK, AKT/PKB, RTKs, ROCK, Ras, Raf, and PI3K all failed
to block CRF-induced CREB phosphorylation. Furthermore, we
ruled out any contribution of calcium to CRF induced CREB
phosphorylation in these neurons.
Alternatively, Gbc could physically interact with and activate
MEK to initiate MAPK signaling. Gbc has been shown to interact
with and activate a variety of downstream signaling molecules,
including AC and ion channels [60]. However, MEK/MAPK are
not among those known be physically regulated by Gbc activation.
Interestingly, Gbc has been shown to traffic to cytoplasmic sites
Figure 6. CRFR1 couples to Gas in striatal neurons. (A) Pre-treatment with pertussis toxin (PTX; 500 ng/mL) did not affect CRF-induced pCREB
(F=11.10). (B) CTX blocked CRF-induced CREB phosphorylation, but had no effect on MAPK-dependent CREB phosphorylation induced by
depolarization (60 K; F=35.15). (C) CRF (4 mM) increased cAMP concentrations in the presence of the cholesterol chelator methyl-b-cyclodextrin
(MbCD; 10 mM).
doi:10.1371/journal.pone.0018114.g006
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and the endoplasmic reticulum [62,63]. It is unknown whether
receptor-mediated activation of Gbc subunits can transduce
cytoplasmic signaling via translocation into the cytoplasm.
However, the hypothesis that Gbc activated at the membrane
can translocate to the cytoplasm to lead to MEK activation cannot
be ruled out. Although beyond the scope of this study, future
investigations in both neuronal and non-neuronal cells will be
needed to determine the exact mechanism by which Gbc leads to
downstream MEK/MAPK activation.
Independent of the mechanism by which Gbc activates
downstream signaling in this paradigm, we hypothesize that the
Gbc subunits released from CRFR1 in response to ligand binding
are unique in their ability to elicit downstream CREB phosphor-
ylation, insofar asdissociationof GbcfromanyGPCRisinsufficient
for this effect. For instance, ISO-mediated activation of b-
adrenergic receptors does not result in Gbc-mediated CREB
phosphorylation (Figure 5B). One hypothesis is that CRFR1-
coupled Gbc subunits have a unique molecular property (i.e. post-
translational modification) that facilitates activation of downstream
signaling pathways. However, our data with the cholesterol chelator
MbCD (Figure 6C) suggest an alternative hypothesis whereby the
sub-cellular localization of CRFR1 in discrete lipid microdomains
allows its dissociated Gbc subunits privileged access to the
downstream signaling machinery necessary for CREB phosphory-
lation, while preventing CRFR1-associated Gas from accessing AC.
Indeed, an emerging theme in neuronal intracellular signaling is the
hypothesis that both membrane-associated and intracellular
signaling proteins are organized into discrete structural and
functional microdomains that facilitate efficacious intracellular
signaling [40]. There is precedent for the organizational influence
of scaffolding proteins and microdomains in neuronal ion channel
and GPCR-mediated CREB phosphorylation. For example, the
privileged ability of L-type calcium channels to mediate down-
stream CREB phosphorylation, at the exclusion of other calcium
influx mechanisms, is due to the specific sub-cellular localization of
these L-channels [64]. Our lab has further shown that caveolin
proteins (CAVs) are necessary for the functional isolation of distinct
GPCR signaling pathways in both hippocampal and striatal
neurons [40,65,66]. Future experiments will test the hypothesis
that functional microdomains and scaffolding proteins, such as
CAVs, mediate signaling specificity in this paradigm.
CRF Signaling in Striatal Neurons
The interaction between stress and drug addiction is well
established. Stress both pre-disposes individuals to drug-addiction,
as well as triggers relapse in previously abstinent addicts [1–3].
Animal models of stress and drug addiction mirror these results
from clinical populations. Stress enhances locomotor responses to
drugs of abuse, and enhances acquisition of self-administration
[53]. Stress has also been shown to re-activate extinguished CPP
for cocaine [4].
CRF is the molecular mediator of many of these effects of stress
on drug taking behavior [67]. Acute administration of drugs of
abuse activates both hypothalamic and extra-hypothalamic CRF,
while CRFadministration mimicsthe effects of stresson drug taking
behaviors in animal models. Since the NAc is thought to be the site
of many of the neuro-plastic changes that underlie drug addiction,
and since CRF has been shown to influence NAc-dependent
behaviors and neurons [11,17,18,68], we hypothesize that CRF
action in NAc neurons underlies some of the effects of stress on
addictive behaviors. It must be noted that NAc is not the sole site of
CRF influence on addiction. In the context of addictive processes,
CRF has been shown to influence several regions of the mesolimbic
dopamine system including the VTA and amygdala [67].
Here we show that CRF can, in fact, directly influence NAc
neurons by activating CREB, a transcription factor that is
important for the responses to stress [69], as well as drug reward
[12]. Our data are consistent with a report showing that stress-
facilitation of drug reward depends on CRFR1 and CREB [11]. It
has been known for quite some time that many of the plastic
changes in NAc neurons required for drug addiction are
dependent on transcription of genes and synthesis of new proteins,
and that the transcription factor CREB plays a key role [13].
This work, which identifies a novel mechanism of CRF signal
initiation at the level of the Gbc subunit in striatal neurons, adds to
a growing literature describing the diverse intracellular signaling
pathways that can be activated by CRF. However, it remains to be
determined whether CRF-induced Gbc signaling is unique to the
striatum, or whether it represents an essential mechanism of CRF
signaling across diverse brain regions. In terms of CRF action in
the striatum, our working hypothesis is that stress-induced release
of CRF into NAc could lead to CREB activation via the pathway
identified here, thus ‘‘priming’’ these neurons for CRE-dependent
transcription following a robust drug-induced stimulus. Conse-
quently, CRF may shift the transcriptional balance towards the
expression of genes that are required for the plastic changes that
characterize addiction, thereby facilitating addictive behaviors.
Future work will be aimed at determining the extent by which
CRF activation of this Gbc pathway underlies the physiological
and behavioral effects of CRF in vivo.
Conclusion
CRF was first described as the neuropeptide that mediated the
HPA response to stress. Since then, CRF has been shown to
modulate a wide variety of brain regions outside of the traditional
HPA axis, including the NAc. Here we report a novel molecular
signaling pathway in striatal neurons in which CRF leads to a
Gbc- and MAPK-dependent increase in CREB phosphorylation.
This pathway not only sheds light on CRF signaling by
characterizing a novel, neuronal CRF initiated signaling pathway,
but also reveals novel potential targets for altering the effects of
CRF on a variety of behaviors.
Figure 7. Proposed mechanism of CRF-induced CREB phos-
phorylation in striatal neurons. CRF binds to Gas-coupled CRFR1,
leading to a Gbc-dependent activation of MEK and MAPK, resulting in
downstream CREB phosphorylation.
doi:10.1371/journal.pone.0018114.g007
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Neuronal Cell Culture
Striatal neurons were cultured from 1- to 2-d-old rat pups as
previously described [65,70], using a protocol approved by the
Animal Care and Use Committee at the University of Minnesota.
Chemicals and drugs were obtained from Sigma (St. Louis, MO)
or Tocris (Ellisville, MO) unless otherwise noted. Following
decapitation, the striatum was isolated in cold HBSS containing
20% fetal bovine serum (FBS; HyClone; Logan, UT), 4.2 mM
NaHCO3, and 1 mM HEPES, pH 7.35 at 300 mOsm. Tissue was
washed before a 5 min digestion in trypsin solution (type XI;
10 mg/mL) containing 137 mM NaCl, 5 mM KCl, 7 mM
Na2HPO4, 25 mM HEPES, and 1500 U of DNase at pH 7.2
and 300 mOsm. For dorsal striatum and central striatum enriched
cultures, a coronal section was made at the level of the striatum.
The dorsal and ventral portions were identified using the anterior
commissure, and then transected using a tungsten needle.
Following additional washes, the tissue was dissociated, and the
cell suspension was pelleted twice before being plated (6610
4 cells
per well) on Matrigel (BD Biosciences; San Jose, CA)-treated
10 mm coverslips. Cells were incubated at RT for 15 min. One
mL of MEM (Invitrogen; Carlsbad, CA) containing 28 mM
glucose, 2.4 mM NaHCO3, 0.0013 mM transferring (Calbio-
chem; La Jolla, CA), 2 mM glutamine, 0.0042 mM insulin, 1% B-
27 Supplement (Invitrogen), and 10% FBS was added to each well.
Forty-eight hrs later, cells received 1 mL of identical media
containing 4 mM cytosine 1-B-D-arabinofuranoside (to inhibit glial
mitosis) and 5% FBS. To limit our analysis to GABAergic medium
spiny neurons, we excluded large cholinergic interneurons from
our analysis based on size.
Drugs
Also see Table S1. Drugs were obtained from Tocris unless
noted. Tetrodotoxin (TTX; 1 mM), D(-)-2-amino-5-phosphono-
pentanoic acid (AP-5; 25 mM), corticotropin releasing factor (CRF;
40 nM), astressin (100 nM), CP154526 (100 nM), K41498
(10 nM), antisauvagine-30 (100 nM); stressin-1 (STR; 70 nM),
H89 (2 mM), forskolin (12.5 mM), PKI, 14–22 amide myristoylated
(1 mM), KT5720 (1 mM), cAMPS-Rp, triethylammonium salt
(10 mM), SQ22536 (90 mM), isoproterenol (10 mM), IBMX
(75 mM), KN-93 (2 mM), nifedipine (5 mM), U0126 (10 mM),
PD98059 (25 mM), K252a (100 nM), 10-DEBC (5 mM), H-1152
(500 nM), GW-5074 (1 mM), Gallein (75 mM), pertussis toxin
(PTX; 500 ng/mL), cholera toxin (CTX; 500 ng/mL; Sigma),
M119 (5 mM; gift from Dr. Kirill Martemyanov), BAPTA-AM
(5 mM; Molecular Probes; Eugene, OR), methyl-b-cyclodextrin
(MbCD; 10 mM; Sigma).
Immunocytochemistry
Protocols followed are those described previously, using a well-
characterized commercially available monoclonal antibody
directed against the Ser133 phosphorylated version of CREB
(see below) [65,66,70–72]. Briefly, cultured striatal neurons (8–10
d.i.v.) were incubated in a Tyrode’s solution containing TTX
(1 mM) and AP-5 (25 mM) at room temperature for 1.5 hr. Unless
noted otherwise, cell stimulations were performed as follows:
vehicle (15 min); agonist stimulations were 15 min, antagonist
exposure was 30 min prior to agonist stimulation, except PTX
and CTX (18 hr pre-treatment), and concurrently with agonist
stimulation. Cells were then fixed for 10 min using ice-cold 4%
paraformaldehyde (Electron Microscopy Sciences; Ft. Washing-
ton, PA) in PBS containing 4 mM EGTA. Following wash, cells
were permeabalized in 0.1% Triton X-100 (VWR Scientific;
West Chester, PA) for 5 min. Following an additional wash, cells
were incubated at 37uC in block solution (1% IgG-Free BSA and
2% Goat Serum (Jackson ImmunoResearch; West Grove, PA) in
PBS) for 30 min. Primary antibody incubation consisted of a 1 hr
incubation at 37uC in block solution containing a monoclonal
antibody directed against the Ser-133 phosphorylated form of
CREB (pCREB 10E9, 1:1000; Upstate Biotechnology, Lake
Placid, NY) and to identify individual cell morphology, a
polyclonal antibody targeting microtubule-associated protein 2
(MAP2, 1:1000; Upstate). For CREB staining (Figure S1), a
rabbit monoclonal antibody directed against total CREB (CREB
48H2, 1:1000; Cell Signaling, Boston, MA) and a mouse
monoclonal antibody directed against a-tubulin (236–10501;
Invitrogen) were used. Cells were then washed before being
incubated in block solution containing FITC- and CY5-
conjugated secondary antibodies (1:200; Jackson ImmunoRe-
search). Following a final wash, cells were mounted using
FluorSave (Calbiochem). Nuclear fluorescent intensities for
pCREB or CREB (approximately 25 cells per group) were
acquired using a Leica DM5500Q confocal system. Data were
quantified with Leica LAS AF (version 1.9.0; Leica).
The confocal excitation and detection settings for each
experiment were determined using coverslips stimulated for
5 min with 60 mM potassium (60 K) to establish a ‘‘ceiling’’ for
pCREB intensity. A baseline was determined via the vehicle (NS)
group, so that each assay has an internal control. Inter-coverslip
variability was accounted for by subjecting 2–3 coverslips to each
treatment. Data were acquired in random order by a blind
observer. Neurons were readily discriminated from glia via size
and morphology (see Figure 1 and Figure S1) and selected
randomly using a-tubulin or MAP2 fluorescence, allowing the
experimenter to remain blind to the CREB or pCREB signal.
Images were captured through the approximate midline of each
neuron. To analyze pCREB fluorescence intensity, the a-tubulin
or MAP2 staining was used to draw a region of interested (ROI) of
interest outlining the nucleus of each neuron. The ROI was then
transferred to the CREB or pCREB image, and average
fluorescence intensities within the nucleus were noted. All images
were background subtracted from an area devoid of neuronal a-
tubulin or MAP2 staining, with each experiment being performed
at least three times to verify results.
cAMP Assay
We measured cAMP concentrations in cultured striatal
neurons (8–10 d.i.v.) using a Parameter cAMP kit (R&D Systems;
Minneapolis, MN) with a mean minimum detectable dose of
1.50 pmol/mL (manufacturer protocol). In all cAMP assays,
striatal neurons were incubated in a Tyrode’s solution containing
TTX (1 mM) and APV (25 mM) for 1.5 hours, and then switched
into an identical solution containing IBMX (75 mM). When
indicated, methyl-b-cyclodextrin (MbCD; 10 mM) was included
with IBMX. For MbCD experiments, 4 mM CRF was used for
15 min (Figure 6C). Stimulations were performed in the presence
of the above compounds for the time-points indicated in
‘‘Results’’ with isoproterenol (10 mM) or CRF. Immediately
following stimulation, neurons were washed with ice-cold PBS
and then lysed with 215 mL ice-cold lysis buffer. Samples were
stored overnight at -20uC before being processed according to
manufacturer instructions. A Bio-Rad microplate reader (model
680) was used to measure concentrations of cAMP. Lysate from
individual coverslips were placed in separate wells (n,4 wells/
group). Each experiment was performed in triplicate to verify
results.
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Cultured striatal neurons were transfected at 7–8 d.i.v. with
1 ug/DNA/coversip using a calcium-phosphate method that
results in .95% of the transfected cells being neurons [70].
Statistics
Experiments were analyzed using ANOVAs and Bonferroni’s
Multiple Comparison post hoc test, or nonlinear curve fits using
Prism 4.03 (GraphPad Software, La Jolla, CA). Statistically
different groups are denoted by different alphabetical characters
in corresponding bar graphs. P-values ,0.05 were considered a
priori as significant. Data are presented as mean 6 SEM.
Supporting Information
Figure S1 CRF does not change total CREB. (A) Im-
munolabeled confocal images of cultured striatal neurons from 1-
to 2-day old rat pups with a-tubulin (green) and total CREB (red).
Neurons stimulated with CRF (40 nM) for 15 min showed no
change in total CREB staining relative to vehicle stimulated
control neurons (NS; Scale Bar = 20 mm). (B) Quantification of
immunostaining revealed no effect of CRF on total CREB staining
(P=0.67, Student’s two-tailed T-test).
(TIF)
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